The immune method

 

(57) Abstract:

The invention relates to the field of therapeutic and preventive medicine and can be used to immunocorrective in the prevention and treatment of seasonal colds accompanied by a reduction in immunity. The method consists in the application of powder spleen pigs received freeze-drying, which is the inside of 0.1-3.0 g per day for 1-4 weeks. The method is simple to use, allows you to increase the shelf life of the biomaterial to 2 years, providing a high therapeutic effect with minimum risk of complications.

The invention relates to the field of therapeutic and preventive medicine and can be used for the prevention and treatment of colds and accompanied by a decrease immune diseases.

Known method of immune and detoxification in the treatment of sepsis, pneumocephaly surgical complications and other serious diseases, which consists in intravenous infusion selenophosphate obtained by a dual perfusion of saline solution through the vascular system of the isolated porcine spleen (see A. B. Tsypin, L. A. Vedernikov. In vitro data 1993, C. 10-13).

The disadvantages of this method are the use of fresh donor spleen, not subject to long-term storage, the complexity of the method and the need to respect the rules of asepsis and antisepsis in the infusion solution.

Known method of immunocorrective in the treatment of indolent wounds, ulcerative colitis, etc. by applying a homogenate of xenoculture (see I. A. Aliev and other Effective methods in clinical practice. Izhevsk, 1993, S. 108 105...).

The disadvantages of this method, taken as a prototype, are cumbersome obtain a homogenate and short term storage.

The essence of the invention lies in the fact that according to the method of immunocorrective, including the use of media, as media use powder spleen pigs received freeze-drying.

The proposed method extends the use of xenoculture, easy to use, allows you to increase the shelf life of the material up to 2 years, shows a high therapeutic effect and minimizes the risk of complications associated with the violation of asepsis.

The claimed method is as follows: for the lead programmed freezing in the low-temperature refrigerator, then freeze-dried and Packed in sterile container.

Powder is the inside of 1.0 g 3 times a day (dosage may be individual - above or below). The duration of treatment is determined by the disease, in acute infections 7-10 days, for the prevention of 7-12 days 1.0 g once daily for the prevention of diseases in children of 0.1 to 1 g once a day for 3-4 weeks. During prolonged low-intensity infections, renal and rheumatoid pathology treatment 1-2 months.

The drug is well combined and prevents negative immunosuppressive action of antibiotics and other anti-inflammatory drugs, which increases therapeutic potential of used drug combinations.

Example 1. Patient P s, 45 years. Diagnosis: acute viral pneumonia.

When using the drug in powder form 1,h times a day for 10 days in combination with antitoxic drugs (gemodez/3 times, antinodes inside 3 days) without antibiotics was noted mild toxic and asthenic syndromes, clinical recovery to 12 days without residual effects. Control served a similar case, where the spleen was not applied (dammah patient pen. before treatment there was an increase JgA, normalizability to 10 days. In control - normalization is not received.

Example 2. The patient In the society, 32 years. Diagnosis: rheumatoid arthritis, active phase II century, FNS II Art.

Received medication spleen in the form of powder 2,h times a day for months. It was noted a distinct positive effect (since the appointment of the drug after 4 days improved the General condition, in a week increased the index of mobility of joints, to the end of the treatment decreased the levels of inflammation in the blood: erythrocyte sedimentation rate, C-reactive protein, sialic acid). Prior to the appointment of the spleen the patient received a combination of nonsteroidal anti-inflammatory drugs (salicylates and indomethacin) without an effect on a background of reception of the spleen has become possible to reduce the dose of anti-inflammatory drugs (indomethacin).

Way immune disorders, including the use of media, characterized in that as media use powder spleen pigs received freeze-drying, which is the inside of 0.1 - 3.0 g per day for 1 to 4 weeks.

 

Same patents:

The invention relates to medicine, in particular for cell therapy and can be used for the treatment of diseases caused by disorders of the immune system, for example, diabetes
The invention relates to ophthalmology

The invention relates to medicine, namely General medicine and dentistry

The invention relates to medicine, namely to methods for preparations from bone marrow, in particular negative regulators of hemopoiesis
The invention relates to medicine, in particular for surgical treatment of musculoskeletal system
The invention relates to medicine, namely the creation of an organ-specific homeopathic drugs for stimulation of myeloid and lymphoid blood sprouts

FIELD: medicine, surgery, transplantology.

SUBSTANCE: embryonic spleen should be sampled, washed in nutritive medium № 199 to be placed into fresh medium № 199 to obtain homogenate in teflon homogenizer followed by centrifuging; then one should isolate the upper, medium and inferior layers, suck off medium layer and the upper part of inferior layer; the cell mixture obtained should be diluted in nutritive medium № 199 to be then introduced by injections into mesentery of small intestine or rectus muscle of abdomen. The present innovation favors the activation of immune system in patients undergone splenectomic operation and in those in case of surgical immunodefficient state due to high functional and regenerating activity of transferred embryonic splenic cells.

EFFECT: higher efficiency of prophylaxis.

6 dwg, 2 tbl

FIELD: medicine.

SUBSTANCE: method involves using mononuclear autologic marrow fraction containing 6-9x104 mesenchyma cells per 1 ml or autologic mesenchyma trunk cells. The cells are separated from brain bioptate in the amount of 106 cells/kg of patient body mass. The preparations are intracoronarily introduced in fractions at a rate of 3-5 ml/min into the right coronary artery. The introduction is also carried out in intra-arterial mode in jets or in drops.

EFFECT: higher survival rate and life quality of cardiologic patients.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing autologic mesenchyma trunk cells as a single intravenous drop dose or in the amount of 1 mln cells per 1 kg of patient body weight.

EFFECT: provided stable clinical remission.

FIELD: medicine, surgery.

SUBSTANCE: method involves every day covering a wound with an agent comprising of pig spleen homogenate and oxygenated with perfluorane taken in the following amounts: 100 g of pig spleen homogenate and 10 ml of oxygenated perfluorane. Invention promotes to accelerating sanitation of suppurative wounds due to activation of topical immunity and activation of regenerating processes. Invention can be used in treatment of suppurative wounds.

EFFECT: improved treatment method of wounds.

2 ex

FIELD: medicine, oncourology.

SUBSTANCE: the present innovation deals with treating locally spread tumor diseases of urinary bladder due to applying either chemo- and/or radiation therapy. Moreover, one should intravenously once inject by drops autologous mesenchymal stem cells (AMSC) at the quantity of 1 mln cells/kg patient's body weight. Moreover, in case of chemotherapy AMSC should be injected during the period before the 20-th d after the last injection of chemopreparation, in case of radiation therapy - 12-15 d against the day of irradiation. In case of chemoradiation therapy AMSC should be injected after chemotherapy before the course of radiation therapy. This method enables to carry out chemoradiation therapy in patients with severe accompanying diseases that prevent such a therapy, and prevent the development of general toxic complications of chemoradiation therapy and medicinal and radiation-caused cystitis.

EFFECT: higher efficiency of therapy.

3 ex, 2 tbl

FIELD: medicine; medical engineering.

SUBSTANCE: biotransplant has genetically unmodified mesenchyma stem cell culture as active component obtained from fetal donor autologous material. The tissue is subjected to disaggregation and the produced cell suspension is resuspended and cultivated on growth medium containing transferrin, insulin, fibroblast growth factor and heparin to accumulate mature stroma in cell culture. Method involves intravenously dropping mesenchyma stem cell culture in the amount of 50 to 500 mln in 50-100 ml of physiologic saline.

EFFECT: accelerated recovery of bone tissue; positive biochemical factors dynamics; improved patient locomotor activity.

6 cl

FIELD: medicine; medical engineering.

SUBSTANCE: biotransplant has genetically unmodified mesenchyma stem cell culture as active component obtained from fetal donor autologous material and genetically unmodified fetal myoblast culture. Method involves intravenously dropping mesenchyma stem cells in the amount of 50 to 500 mln in 50-100 ml of physiologic saline. The fetal myoblast culture is intramuscularly introduced at a dose of 100 mln of cells per 10 kg.

EFFECT: enhanced effectiveness in repairing incretory function of pancreas and reducing resistance to insulin; reduced risk of nephropathy and other complications.

9 cl

FIELD: medicine, cardiology.

SUBSTANCE: one should introduce the suspension of autologous mononuclear medullary cells without preliminary cultivation in to the mouth of coronary artery nourishing infarction area. Cell suspension should be introduced at the quantity of 100-150 mln. cells immediately after stenting coronary artery due to technique of passive passage. The procedure should be performed on the 14th - 21st d against the onset of the disease mentioned. The method provides efficient counterbalance of cardiomyocytes due to applying valuable stem cells at excluding complications induced by arterial occlusion.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

FIELD: medicine, in particular hematology.

SUBSTANCE: CBA/CaLac intact mouse spleen is homogenized in medium containing 95 % of RPMI-1640 and 5 % of ethyl silicate; filtered through nylon grid; washed by centrifugation with RPMI-1640. at 1500 rpm for 10-15 min; final concentration of living splenocites is adjusted to 2x106 colony/ml using media containing 10 % of ethyl silicate, 1 % of L-glutamine; 0.2 % of gentamycine, 0.05 % of mercaptoethanol, 89 % of RPMI-1640; obtained product is cultivated at 37°C for 6 days, centrifuged and supernatant containing target product is separated followed by storage at -20°C. Before filtering 1 ml of distilled water is added in sterile spleen homogenate and after 25 sec 10 ml of RPMI-1640 medium is added. Target product is stored for 1 month or less.

EFFECT: method of improved accuracy and validity.

1 tbl

FIELD: medicine, in particular uses of viruses for cell elimination.

SUBSTANCE: invention relates to uses of viruses capable of reducing undesired cells in ex vivo mixtures of normal marrow or peripheral blood cells and tumor cells, such as leucosis or lymphoma cells due to interaction of abovementioned mixture with vesicular stomatitis virus. Invention also relates to method for malignant tumor treatment in mammalian. Claimed method includes sampling of mammalian marrow or peripheral blood cells; interaction of said cells ex vivo with vesicular stomatitis virus; mieloablative therapy; and transplantation of purified hematopoietic cells into mammalian. In another embodiment invention relates to method for malignant tumor treatment in mammalian having transplant of marrow or peripheral blood stem cells. Said method includes interaction ex vivo of collected transplant cell with vesicular stomatitis virus and administration of these purified cells in mammalian. Method of present invention makes it possible to reduce risk of malignant tumor backset in mammalian with transplanted hematopoietic cells.

EFFECT: new agent for elimination of marrow or peripheral blood tumor cells.

12 cl, 4 ex, 3 tbl

Up!